-
Signature
-
/s/ Maricel Apuli
-
Issuer symbol
-
BBIO
-
Transactions as of
-
16 Feb 2026
-
Net transactions value
-
-$365,160
-
Form type
-
4
-
Filing time
-
18 Feb 2026, 18:39:24 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Apuli Maricel |
Chief Accounting Officer |
C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO |
/s/ Maricel Apuli |
18 Feb 2026 |
0002058197 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
BBIO |
Common Stock |
Tax liability |
$327,262 |
-4,349 |
-3.4% |
$75.25 |
124,455 |
16 Feb 2026 |
Direct |
F1, F2 |
| transaction |
BBIO |
Common Stock |
Sale |
$37,898 |
-510 |
-0.41% |
$74.31 |
123,945 |
17 Feb 2026 |
Direct |
F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: